UPSTREAM
29.1.2020 18:57:04 CET | Business Wire | Press release
93 percent of total mobile transactions in 20 countries were blocked as fraudulent in 2019 according to a report on the state of malware and mobile ad fraud released today by mobile technology company, Upstream . The “Invisible Digital Threat ” data is based on deployments of Upstream’s Secure-D full-stack anti-fraud platform that detects and blocks fraudulent mobile transactions mostly originated from ad fraud malware. The platform at the end of 2019 covered 31 mobile operators in 20 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200129005647/en/
In the markets examined, Upstream’s security platform processed 1.71 billion mobile transactions and blocked 1.6 billion of them as fraudulent , a staggering 93 percent of total transactions . It is estimated that left unchecked these transactions would have cost users $2.1bn in unwanted charges . For the industry as a whole, losses from online, mobile and in-app advertising reached $42 billion in 2019 and are expected to reach $100 billion by 20231 .
The number of malicious apps discovered by Secure-D in 2019 rose to 98,000 , up from 63K in 2018. These 98,000 malicious apps had infected 43 million Android devices .
With Android devices now accounting for an estimate 75-85% of all smartphone sales worldwide2 Android is by far the most dominant mobile operating system (OS). At the same time it is the most vulnerable due to its open nature, making it a favorite playground for fraudsters.
While, as mentioned in the Secure-D report, it is always a good rule of thumb for consumers to only download mobile applications from Google’s official storefront, Google Play, thanks to its scale and set up, rogue apps are still getting through its defences. Of the top 100 most active malicious apps that were blocked in 2019, 32 percent are reported still available to download on Google Play . A further 19 percent of the worst-offending apps were previously on Google Play but have since been removed, while the remaining 49 percent are available through third-party app stores.
Fraudsters appear to target some app categories more than others. Ironically, apps designed to make a device function better and make everyday life easier are the ones most likely to be harmful with 22.32 percent of malicious apps for 2019 falling under the Tools / Personalization / Productivity category 3 globally. The next most popular categories cybercriminals target are Games (18.97 percent) and Entertainment/Shopping (15.76 percent).
Indicating scale, in the course of only a few months in 2019, Secure-D reported on the suspicious background activity of five very popular Android apps: 4shared, a popular file-sharing app, Vidmate, a video downloader, Weather Forecast a preinstalled app on Alcatel devices, Snaptube, another video and audio app, and ai.type, an on-screen keyboard app. With a total of nearly 700 million downloads, these were or had been at some point available on Google Play. In these five cases alone, Secure-D detected and blocked 353 million suspicious mobile transactions preventing $430 million in fraudulent charges.
Dimitris Maniatis, CEO of Upstream commented, "Mobile ad fraud is a criminal enterprise on a massive scale. Though it may seem that it is only targeted at advertisers, it greatly affects the whole mobile ecosystem. Most importantly it adversely impacts consumers; eating up their data allowance, bringing unwanted charges, messing with the performance of their device, and even targeting and collecting their personal data. It is more than an invisible threat, it is an epidemic, calling for increased mobile security that urgently needs to rise up in the industry’s priority list. Left unchecked, ad fraud will choke mobile advertising, erode trust in operators and lead to higher tariffs for users" .
The effects of mobile ad fraud are particularly damaging in emerging markets where data costs are significantly higher. As evidenced from detailed data presented from five such markets including Brazil and South Africa fraud rates in most cases exceed the 90% mark. As Upstream’s report highlights consumers in emerging markets are more vulnerable to digital fraud; they are unaware of the dangers as they often go online for the first time via their mobile devices and data depletion caused by malware has a much greater effect on them due to the high cost of data in their countries. In Africa 1 GB of data costs prepaid mobile subscribers the equivalent of 16 hours of work at minimum wage.
Download the full report for an in-depth look at the state and workings of mobile ad fraud including insights on five emerging markets: Brazil, Egypt, Indonesia, South Africa and Ethiopia . By way of comparison, the report also juxtaposes snapshots of the state of malware in the United Kingdom and USA.
-ENDS-
1 Juniper Research
2 Statista and Statcounter
3 As these categories are Google Play Store specific, percentages apply only to apps currently or previously available on Google Play
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
